This information was provided by aleafiainc
Send your Press Release here.
Patient Data, Intellectual Property to be Used in Development of Proprietary Products
TORONTO, October 29, 2018 /Globe Newswire/ – Aleafia Health Inc. (TSXV: ALEF; OTCQX: ALEAF, FRA: ARAH) (“Aleafia“) or (the “Company“), a highly differentiated cannabis company with major cannabis cultivation and medical clinic operations is formally launching a research, development and innovation division to be called Aleafia Labs (“Aleafia Labs”).
Aleafia Labs will leverage the company’s existing patient database and intellectual property to advance the development of proprietary cannabis products. R&D activities will focus on the development of cannabis products that may act as a replacement for addictive prescription opioids and sleeping aids.
Dr. Gary Goodyear, Aleafia’s President of Clinic Operations, led the Government of Canada’s research and innovation programs as the federal Minister of State for Science and Technology. Aleafia previously announced a medical cannabis sleep study with Cronos Group Inc. (NASDAQ: CRON) (TSX: CRON) and expects to announce a new biotechnology study in the near term.
“Aleafia is uniquely positioned to develop intellectual property and commercial products following a data-driven approach,” said President of Clinic Operations, Dr. Gary Goodyear. “While the relationship most cannabis companies have with their patients ends at the point of sale, our physicians closely monitor and track a patient’s progress throughout the entire treatment cycle. This unique data will lead to the development of innovative cannabis products.”
“For far too long, the answer to a patient’s sleeping disorder or chronic pain has been a prescription and a bottle of pills,” said Aleafia Chief Medical Officer Dr. Michael Verbora. “With a clinical approach to research and development, we will be able to tackle some of the largest public health problems of our time.”